Stock Detail
REXAHN PHARMACEUTICALS INC
Biotechnology
RNN @ Yahoo Finance | RNN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.51 | $0.51 | $0.04 | 8.11% | 0.00 | $0.47 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.48 | $0.47 | 340,451 | 48.16M | 348,101.5 | -3.16 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.54 | 0.53 | 0.50 | 0.49 | 0.46 |
Stock Profile
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its products portfolio comprises Archexin, a Phase II clinical trials product for the treatment of renal cell carcinoma; Serdaxin, a Phase II clinical trials initiated product for the treatment of depression and mood disorders; and Zoraxel, a CNS-based sexual dysfunction drug, which is a Phase II clinical trials initiated product for the treatment of erectile dysfunction. The company's pre-clinical pipeline products include RX-0201-Nano, a nanoliposomal anti-cancer Akt-1 inhibitor; RX-0047-Nano, a nanoliposomal anti-cancer HIF-1 alpha inhibitor; and Nano-polymer anticancer drugs. Rexahn Pharmaceuticals has collaboration and license arrangements with UPM Pharmaceuticals, Inc.; Korean Research Institute of Bioscience and Biotechnology; Ewha Womans University; Amarex, LLC; Korea Research Institute of Chemical Technology; The University of Maryland; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Formatech, Inc. The company is based in Rockville, Maryland.